Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: JCO Precis Oncol. 2024 Apr;8:e2300635. doi: 10.1200/PO.23.00635

FIG 2.

FIG 2.

OS (A) of all patients who initiated protocol therapy and (B) after excluding patients who crossed over to gemcitabine/berzosertib, (C) of all patients with a PFI of 3 months or less who initiated protocol therapy and (D) after excluding patients who crossed over to gemcitabine/berzosertib, and (E) of all patients with a PFI of more than 3 months to <6 months who initiated protocol therapy and (F) after excluding patients who crossed over to gemcitabine/berzosertib. HR, hazard ratio; OS, overall survival; PFI, platinum-free interval.